Abstract
Anthracyclines have been widely used in cancer therapy due to their efficacy in the treatment of various solid tumors and hematologic malignancy. Cumulative dose-related cardiotoxicity is a well-known toxicity of anthracyclines. Particularly, at total doses of more than 550 mg/m 2 , therapy with anthracyclines can produce irreversible cardiac injury. Anthracycline-induced cardiac toxicity usually manifests by congestive heart failure or arrhythmia. In contrast, acute myocardial infarction is a rare event of anthracycline-induced heart diseases. A 31-year-old man with non-Hodgkin lymphoma (NHL and a single cardiac risk factor, smoking, presented with chest pain after receiving a 2 nd round of CEOP-BLAM chemotherapy. An electrocardiogram revealed ST segment elevation in the inferior leads consistent with acute myocardial infarction. An echocardiogram revealed an ejection fraction of 60% and severe hypokinesia in the inferior wall. Three days later, coronary angiography revealed 50% of luminal stenosis of right coronary artery (RCA and near total occlusion with a large thrombi in the m-RCA. Following balloon angioplasty and stent insertion, the patient was transferred to the coronary care unit and continuous intravenous heparin infusion was started. On the 10th day, the patient was discharged in good condition. Six months later, follow-up coronary angiography showed no significant lesion in the right coronary artery. In a young man with NHL, we report an acute myocardial infarction after a 2nd course of CEOP-BLAM chemotherapy with a review of the relevant literature. (Korean Circulation J 2001;30(5 :507-511
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
